Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib in NRAS mutant non-melanoma solid tumors
NCT07170293Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Aug 2027
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib in solid tumor, sponsored by The Second Hospital of Tianjin Medical University. Planned start Aug 2027; status: recruiting.
02
Drugs
tunlametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07170293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170293.